Drug Type AAV based gene therapy |
Synonyms BBM D101, BBMD101 |
Target |
Mechanism UTRN modulators(Utrophin modulators), dystrophin modulators(Dystrophin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Belief BioMed, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
RegulationOrphan Drug (US), Rare Pediatric Disease (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Phase 1 | CN | 25 Jul 2024 | |
Muscular Dystrophy, Duchenne | Phase 1 | CN | 25 Jul 2024 |